Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of … Read more
Crispr Therapeutics AG (CRSP) - Total Liabilities
Latest total liabilities as of December 2025: $343.43 Million USD
Based on the latest financial reports, Crispr Therapeutics AG (CRSP) has total liabilities worth $343.43 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Crispr Therapeutics AG - Total Liabilities Trend (2014–2025)
This chart illustrates how Crispr Therapeutics AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Crispr Therapeutics AG Competitors by Total Liabilities
The table below lists competitors of Crispr Therapeutics AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Marico Limited
NSE:MARICO
|
India | ₹44.73 Billion |
|
China Natl Chem Engineering Co
SHG:601117
|
China | CN¥170.17 Billion |
|
Paylocity Holdng
NASDAQ:PCTY
|
USA | $5.87 Billion |
|
Hoa Phat Group JSC
VN:HPG
|
Vietnam | ₫126.70 Trillion |
|
Atour Lifestyle Holdings Limited American Depositary Shares
NASDAQ:ATAT
|
USA | $5.26 Billion |
|
Telefônica Brasil S.A.
SA:VIVT3
|
Brazil | R$55.40 Billion |
|
Primo Brands Corporation
NYSE:PRMB
|
USA | $7.80 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Crispr Therapeutics AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Crispr Therapeutics AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Crispr Therapeutics AG (2014–2025)
The table below shows the annual total liabilities of Crispr Therapeutics AG from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $343.43 Million | +10.80% |
| 2024-12-31 | $309.95 Million | -10.62% |
| 2023-12-31 | $346.77 Million | -5.66% |
| 2022-12-31 | $367.58 Million | +4.30% |
| 2021-12-31 | $352.42 Million | +115.24% |
| 2020-12-31 | $163.73 Million | +28.59% |
| 2019-12-31 | $127.33 Million | +31.51% |
| 2018-12-31 | $96.82 Million | +15.93% |
| 2017-12-31 | $83.51 Million | -25.51% |
| 2016-12-31 | $112.12 Million | -40.54% |
| 2015-12-31 | $188.55 Million | +2117.94% |
| 2014-12-31 | $8.50 Million | -- |